Method for rapidly preparing high-purity ginsenoside Rd by utilizing enzyme reaction membrane separation coupling technology
The conversion of ginseng saponin Rb1 into ginseng saponin Rd through enzyme reaction membrane separation and coupling technology solves the problems of high costs in the existing technology and the inability to reuse enzymes, realizes a high purity and efficient production process, reduces production costs and improves catalysis performance.
Patent Information
- Application Number
- CN202411327239.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-23
- Publication Date
- 2024-12-03
AI Technical Summary
In the prior art, the production of ginseng saponin Rd has the problem of using a large number of organic solvents, complex purification devices and high costs, and free enzymes cannot be reused, which may lead to saponin degradation at long-term high temperatures, and the enzyme contaminated layer affects catalytic activity.
Using enzyme reaction membrane separation and coupling technology, β-glucosidase is fixed on the ultrafiltration membrane, and a biocatalytic membrane is formed by modification treatment. The membrane is used to convert ginseng saponin Rb1 into ginseng saponin Rd to achieve continuous catalysis and reduce production costs. .
The rapid preparation of high-purity ginseng saponin Rd is achieved, which reduces production costs, extends the catalytic time of enzymes, avoids enzyme degradation and contamination of layers, and improves the catalytic performance and the purity of products.
Smart Images

Figure CN119061103A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of drug preparation, and specifically relates to a method for rapidly preparing high-purity ginsenoside Rd by utilizing enzyme reaction membrane separation coupling technology. Background Art
[0002] Ginsenoside Rd has excellent neuroprotective, anti-inflammatory and antioxidant activities. However, due to the low content of ginsenoside Rd in medicinal materials such as ginseng, Panax notoginseng, and American ginseng, obtaining ginsenoside Rd directly from plants requires the use of a large amount of organic solvents and complex purification equipment, which is environmentally unfriendly and costly, and is not conducive to the large-scale production of ginsenoside Rd. In contrast, ginsenoside Rb1 is more abundant in plants. Its structure has one more glucose at the C-20 position than ginsenoside Rd, and it can be hydrolyzed under the action of β-glucosidase to produce the product ginsenoside Rd.
[0003] In the prior art, free β-glucosidase is used to convert ginsenoside Rb1 into ginsenoside Rd, but there are problems such as the free enzyme cannot be reused and long-term high reaction temperature may cause saponin degradation. The reverse filtration method is used to prepare the biocatalytic membrane, which is prone to form an enzyme contamination layer, affecting the enzyme configuration and the exposure of the active site, thereby affecting the catalytic activity of the enzyme. Summary of the invention
[0004] The purpose of the present invention is to provide a method for rapidly preparing high-purity ginsenoside Rd by using enzyme reaction membrane separation coupling technology, which can continuously convert ginsenoside Rb1 into ginsenoside Rd, has a high conversion rate, a long enzyme catalysis time, and significantly reduces the production cost.
[0005] The purpose of the present invention is achieved by the following technical solutions:
[0006] A method for rapidly preparing high-purity ginsenoside Rd by using enzyme reaction membrane separation coupling technology comprises the step of converting ginsenoside Rb1 into ginsenoside Rd by using a biocatalytic membrane fixed with β-glucosidase.
[0007] In the present invention, the biocatalytic membrane immobilized with β-glucosidase is obtained by immobilizing a β-glucosidase solution on an ultrafiltration membrane through ultrafiltration. During the ultrafiltration process, the β-glucosidase solution flows from the support layer to the epidermis of the ultrafiltration membrane.
[0008] In the present invention, the conditions for fixing the β-glucosidase solution on the ultrafiltration membrane by ultrafiltration are: operating pressure of 1.5-3 bar, temperature of 20-30° C., stirring speed of 150-250 rpm; the solvent in the β-glucosidase solution is acetate or phosphate buffer with a pH of 5.0 to 7.0.
[0009] In the present invention, the ultrafiltration membrane immobilized with β-glucosidase is modified by using a solution containing dopamine hydrochloride and polyallylamine hydrochloride, the stirring speed during the modification process is 50-400 rpm, and the modification time is 1-4 hours.
[0010] In the present invention, the concentration of dopamine hydrochloride in the solution containing dopamine hydrochloride and polyallylamine hydrochloride is 1-3 g / L, and the concentration of polyallylamine hydrochloride is 1-3 g / L; the solvent containing the solution containing dopamine hydrochloride and polyallylamine hydrochloride is a Tris-HCl buffer solution with a pH of 8.5 to 9.5.
[0011] In the present invention, during the conversion process, the ginsenoside Rb1 solution is ultrafiltered using a biocatalytic membrane fixed with β-glucosidase, the membrane flow rate of the ginsenoside Rb1 solution is 1-3 mL / min, and the temperature is 40-70°C; the solvent of the ginsenoside Rb1 solution is a buffer solution with a pH of 3.5 to 6.5.
[0012] In the present invention, the molecular weight cut-off of the ultrafiltration membrane is 10000 to 30000 Da.
[0013] In the present invention, the material of the ultrafiltration membrane is polyethersulfone, sulfonated polyethersulfone, cellulose acetate, regenerated cellulose or sulfonated polysulfone.
[0014] In the present invention, ginsenoside Rb1 is converted into ginsenoside Rd through a biocatalytic membrane, and then cooled to 0-5° C., and the precipitate is freeze-dried to obtain ginsenoside Rd.
[0015] In the present invention, the purity of ginsenoside Rb1 is ≥70%.
[0016] Compared with the prior art, the present invention has the following beneficial effects: the present invention utilizes enzyme reaction membrane separation coupling technology to convert ginsenoside Rb1 into ginsenoside Rd that can be precipitated at low temperature, and the beneficial effects are as follows: ① β-glucosidase converts low-purity ginsenoside Rb1 into ginsenoside Rd, and high-purity ginsenoside Rd can be obtained by solid-liquid separation method without organic reagents. ② The solubility of ginsenoside Rd increases with the increase of temperature and ginsenoside Rb1 concentration. The present invention utilizes this characteristic to cool the solution after β-glucosidase conversion, and ginsenoside Rd can be precipitated in solid form to achieve directional separation. ③ The present invention successfully fixes β-glucosidase on the membrane to prepare a biocatalytic membrane, which can be recycled for a long time, retains strong catalytic activity, and realizes the continuous conversion of ginsenoside Rb1. Dopamine hydrochloride and polyallylamine hydrochloride are added during the preparation process for co-precipitation modification. This method can well regulate the redispersion of the enzyme contamination layer in the membrane, and effectively improves the catalytic performance of the biocatalytic membrane. ④ In this method, the separation of the product from the system utilizes the different solubilities of different saponins after conversion, and cleverly uses membrane separation to achieve directional separation of ginsenoside Rd. In addition, the continuous flow catalysis of the biocatalytic membrane well solves the enzyme recovery problem existing in other immobilized carriers. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 Enzyme dispersion in the biocatalytic membrane modified with dopamine hydrochloride.
[0018] Figure 2 The enzyme dispersion in the biocatalytic membrane modified from a solution containing dopamine hydrochloride and polyallylamine hydrochloride.
[0019] Figure 3 It is a liquid chromatogram of the components in a 70% ginsenoside Rb1 solution, a converted solution (i.e., a permeate), a filtrate (a filtrate filtered after the permeate is cooled to a low temperature), and a filter cake (a filter cake filtered after the permeate is cooled to a low temperature).
[0020] Figure 4 Ginsenoside Rd is obtained by transforming low-purity ginsenoside Rb1. DETAILED DESCRIPTION
[0021] Example 1
[0022] The method of the present invention for rapidly preparing high-purity ginsenoside Rd by using enzyme reaction membrane separation coupling technology comprises the following steps:
[0023] (1) To 1 mL of 2000 U / g β-glucosidase from Aspergillus niger (Nantong Feiyu Biotechnology Co., Ltd.), 49 mL of 20 mM acetate buffer solution at pH 7.0 was added to obtain a diluted β-glucosidase solution.
[0024] (2) A UE030 polyethersulfone ultrafiltration membrane (purchased from Zhongke Ruiyang Membrane Technology (Beijing) Co., Ltd., with a molecular weight cutoff of 30,000 Da) was placed with the support layer facing up and the skin layer facing down on an effective membrane area of 41.8 cm 2 into an ultrafiltration cup. Subsequently, 50 mL of the diluted β-glucosidase solution was added to the ultrafiltration cup, and the pressure was provided by high-pressure nitrogen. Ultrafiltration was performed under the conditions of an operating pressure of 2 bar, a temperature of 25°C, and a stirring speed of 200 rpm. When the volume of the permeate reached 45 mL, the ultrafiltration was stopped, 25 mL of ultrapure water was added to the ultrafiltration cup, and ultrafiltration was performed at an operating pressure of 2 bar and a temperature of 25°C. The ultrafiltration membrane was rinsed, and the rinsing was stopped when the volume of the permeate reached 15 mL. 30 mL of Tris-HCl buffer solution (pH 8.5) containing 2 g / L dopamine hydrochloride and 2 g / L polyallylamine hydrochloride (Mw = 15 KDa) was added to the ultrafiltration cup, and the ultrafiltration membrane immobilized with β-glucosidase was modified at 25°C and a stirring speed of 200 rpm. The modification time was 2 h to obtain a PDA / PAH biocatalytic membrane. After the modification, 400 mL of ultrapure water was added to the ultrafiltration cup, and the biocatalytic membrane was cleaned by ultrafiltration at an operating pressure of 2 bar and 25 ° C for 20 minutes. After the cleaning, the liquid in the ultrafiltration cup was discarded, the PDA / PAH biocatalytic membrane was taken out, and the support layer was placed downward and the epidermis layer was placed upward in the original ultrafiltration cup for subsequent conversion reactions. After detection and calculation, the amount of enzyme fixed on the ultrafiltration membrane was 5.32 mg.
[0025] (3) Weigh 633.9 mg of ginsenoside Rb1 with a purity of 70% (Nanjing Jingzhu Biotechnology Co., Ltd., B105092), add it to 100 mL of acetate buffer solution with a pH of 4.0 and a concentration of 20 mM, dissolve it by ultrasonication, and dilute it to 200 mL to obtain a 2 mM ginsenoside Rb1 solution. The ginsenoside Rb1 solution is added to the ultrafiltration cup (PDA / PAH biocatalytic membrane epidermis facing upward) equipped with the PDA / PAH biocatalytic membrane obtained in step (2) for ultrafiltration, and the membrane flow rate is controlled to be 2.2 mL / min, and the operating temperature is 55°C. Ginsenoside Rb1 is converted into ginsenoside Rd under the catalysis of the PDA / PAH biocatalytic membrane and enters the permeate. After the permeate is cooled to 4°C, ginsenoside Rd is precipitated, and solid-liquid separation is performed using a 0.22 μm microfiltration membrane. The precipitate is rinsed 2-3 times with deionized water at 4°C and then freeze-dried ( Figure 4 ). 2 mM ginsenoside Rb1 solution (70% ginsenoside Rb1 solution), permeate (converted solution), filtrate filtered after the permeate was cooled to 4°C, and filter cake (i.e., precipitate) filtered after the permeate was cooled to 4°C were detected by HPLC ( Figure 3), no ginsenoside Rb1 was detected in the permeate, and it was almost completely converted into ginsenoside Rd, with a conversion rate of 96.3%. The purity of the obtained ginsenoside Rd was 90.5%, and the yield was 51.8%.
[0026] Comparative method 1 for preparing ginsenoside Rd: The method for rapidly preparing high-purity ginsenoside Rd by using enzyme reaction membrane separation coupling technology of the present invention is carried out, except that in step (2), 30 mL of Tris-HCl buffer solution (pH 8.5) containing 2 g / L dopamine hydrochloride is added to the ultrafiltration cup during modification, and the modification is carried out at 25° C. and stirring speed of 200 rpm for 2 h to obtain a control biocatalytic membrane. According to calculation, the amount of enzyme fixed on the control biocatalytic membrane is 6.14 mg. During the conversion process of 2 mM ginsenoside Rb1 solution, when ultrafiltration is carried out at a membrane flow rate of 2.2 mL / min and a temperature of 55° C., the conversion rate of ginsenoside Rb1 by the biocatalytic membrane is only 35.6%, and ginsenoside Rd is not precipitated in the permeate after cooling.
[0027] The catalytic effect of the PDA / PAH biocatalytic membrane modified with a solution containing dopamine hydrochloride and polyallylamine hydrochloride was much better than that of the biocatalytic membrane modified with dopamine hydrochloride alone. Even though the enzyme immobilization amount was lower than that of the latter, the results of laser confocal microscopy showed that the enzyme dispersion of the former was better ( Figure 1 ) is better than the latter ( Figure 2 ), more dispersed enzymes avoid blocking the active center of the enzyme, resulting in better catalytic effects.
[0028] Control method 2: Use free enzyme to convert low-purity ginsenoside Rb1. Add 200 mg of ginsenoside Rb1 with a purity of 70% to a 250 mL fermentation bottle, add 100 mL of pH 4.0, 20 mM acetate buffer solution, and dissolve it by ultrasound. Then add 100 μL of β-glucosidase solution (2000 U / g) from Aspergillus niger, react for 30 minutes under 55°C water bath conditions, and cool the converted solution to 4°C. At this time, the solution changes from clear to turbid. The above turbid solution is separated from the solid by a 0.22 μm microfiltration membrane, and the solid on the microfiltration membrane is rinsed with 4°C pure water 2 to 3 times and then freeze-dried. According to HPLC detection, no ginsenoside Rb1 was detected in the reaction solution, and it was almost completely converted into ginsenoside Rd, with a conversion rate of 96.3%. The purity of the obtained ginsenoside Rd was 90.7%, and the yield was 50.9%. However, free enzyme conversion is difficult to carry out continuous production, and batch reactions at high temperatures for a long time will lead to saponin degradation, affecting product purity and yield.
Claims
1. A method for rapidly preparing high-purity ginsenoside Rd using enzyme reaction membrane separation coupling technology, Features The method comprises the steps of converting ginsenoside Rb1 into ginsenoside Rd by using a biocatalytic membrane fixed with beta-glucosidase.
2. The method according to claim 1, Features The biocatalytic membrane fixed with β-glucosidase is obtained by fixing the β-glucosidase solution on the ultrafiltration membrane through ultrafiltration. During the ultrafiltration process, the β-glucosidase solution flows from the support layer to the epidermis of the ultrafiltration membrane.
3. The method according to claim 2, Features The conditions for fixing the β-glucosidase solution on the ultrafiltration membrane by ultrafiltration are: operating pressure of 1.5-3 bar, temperature of 20-30° C., stirring speed of 150-250 rpm; the solvent in the β-glucosidase solution is acetate or phosphate buffer with a pH of 5.0-7.
0.
4. The method according to claim 1, 2 or 3, Features The ultrafiltration membrane fixed with β-glucosidase is modified by using a solution containing dopamine hydrochloride and polyallylamine hydrochloride. The stirring speed during the modification process is 50-400 rpm and the modification time is 1-4 hours.
5. The method according to claim 4, Features The concentration of dopamine hydrochloride in the solution containing dopamine hydrochloride and polyallylamine hydrochloride is 1-3 g / L, and the concentration of polyallylamine hydrochloride is 1-3 g / L; the solvent of the solution containing dopamine hydrochloride and polyallylamine hydrochloride is Tris-HCl buffer solution with pH 8.5-9.
5.
6. The method according to claim 5, Features During the conversion process, the ginsenoside Rb1 solution is ultrafiltered using a biocatalytic membrane fixed with β-glucosidase, the membrane flow rate of the ginsenoside Rb1 solution is 1-3 mL / min, and the temperature is 40-70° C. The solvent of the ginsenoside Rb1 solution is a buffer solution with a pH of 3.5 to 6.
5.
7. The method according to claim 3, Features The molecular weight cut-off of the ultrafiltration membrane is 10000-30000Da.
8. The method according to claim 7, Features The material of the ultrafiltration membrane is polyethersulfone, sulfonated polyethersulfone, cellulose acetate, regenerated cellulose or sulfonated polysulfone.
9. The method according to claim 8, Features After ginsenoside Rb1 is converted into ginsenoside Rd through a biocatalytic membrane, it is cooled to 0-5°C, and the precipitate is freeze-dried to obtain ginsenoside Rd.
10. The method according to claim 9, Features The purity of the ginsenoside Rb1 is ≥70%.
